Advertisement

Advertisement

News

Fixed-Dose Pertuzumab-Based Regimen Under Study in FeDeriCa Trial

News

AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC

News

AACR 2021: Overall Survival Update From IMmotion151 in Advanced Kidney Cancer

Medical Literature

Immune Checkpoint Inhibitors and Kidney Cancer: Immune-Related Adverse Events and Outcomes

Medical Literature

Case Study: Immunomodulatory Mechanism and Antimyeloma Effect of Daratumumab

Medical Literature

IMWG Offers Updated Recommendations for Managing Myeloma-Related Bone Disease

News

AACR 2021: Combination Targeted Therapies Under Study in Resistant Kidney Cancer

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Trial Results of IMMU-132

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

View More

Advertisement

JNCCN Spotlights

(UPDATE) Pembrolizumab (NSCLC)

(UPDATE) Daratumumab (MM)

View More

More

News

Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial

Immunotherapy for Urothelial Cancer: Balancing Benefits and Risks

Cemiplimab-rwlc Monotherapy and PD-L1 Expression in Advanced NSCLC

Comparing Immunotherapy Regimens in Metastatic Kidney Cancer

Novel Vaccine Under Study in Basal Cell Carcinoma

AACR 2021: Overall Survival Update From IMmotion151 in Advanced Kidney Cancer

Cardiac Repolarization After Daratumumab Monotherapy for Smoldering Multiple Myeloma

AACR 2021: Survival Outcomes by Treatment Response From IMvigor130 in Urothelial Cancer

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

High-Rick Relapsing MM: Retreatment With Immunomodulatory Therapy

JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

View More

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.